Visit us at the ATA 2022 Annual Meeting – Booth 1011

Two Novel microRNA Pairwise Expression Profilers Complement Multiplatform Molecular Testing (MPTX), Providing More Accurate Diagnosis of Indeterminate Thyroid Nodules

ATA Annual Meeting 2021 (online)

The goal of molecular testing for indeterminate thyroid nodules (ITNs) is to accurately distinguish patients who would likely benefit from conservative management from those who would benefit from surgical intervention. When incorporated into molecular assessment of ITNs, quantitative microRNA expression has been shown to improve the prediction of nodule status over reliance on mutation detection alone.

We analyzed the value of microRNA pairwise expression analysis, using two new microRNA Profilers (Benign/Malignant and Specific Strong-driver) in conjunction with MPTX (Multiplatform testing with ThyGeNEXT® + ThyraMIR®)

Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.

Scroll to Top